Peptide Library / Detail
PNC-27
Half-life
Not well characterized; expected short plasma stability typical of linear peptides (minutes to low hours) without specialized formulation
Delivery
Preclinical studies have explored intratumoral, perilesional, or topical/locoregional administration; systemic delivery remains investigational.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
PNC-27 is a synthetic peptide based on residues from the human p53 protein linked to a membrane-penetrating motif. In preclinical research it binds HDM2 localized on cancer-cell membranes and assembles into membrane pores, producing selective on-target cytotoxicity in vitro and in animal models.
Usage
Exploratory oncology research to study HDM2-targeted membrane disruption, tumor cell killing, and differential effects between malignant and non-malignant cells.
Mechanism of Action
Binds HDM2 on cancer-cell membranes; peptide oligomerization forms transmembrane pores that rapidly disturb ionic gradients and induce necrotic/apoptotic cell death. Selectivity is hypothesized to stem from cancer-specific membrane HDM2 expression.
Benefits(3)
- Potent cytotoxicity against HDM2-positive cancer cells in vitro
- Activity reported across multiple tumor cell lines in preclinical studies
- Mechanistically distinct from DNA-damaging chemotherapeutics
Side Effects(3)
- Local irritation at administration site (preclinical)
- Potential off-target membrane toxicity/hemolysis at higher concentrations
- Unknown immunogenicity and systemic safety; not clinically approved